Global Cancer Cachexia Market Overview to 2027

DUBLIN, May 27, 2022 /PRNewswire/ — The report “Cancer Cachexia Market: Global Industry Trends, Share, Size, Growth, Opportunities and Forecast 2022-2027” has been added to from ResearchAndMarkets.com offer.

The Global Cancer Cachexia Market Reached A Value Of US$1.88 billion in 2021. Going forward, the market is expected to reach a value of US$2.53 billion by 2027, posting a CAGR of 4.80% over the period 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst continuously monitors and assesses the direct and indirect influence of the pandemic. This information is included in the report as a major market contributor.

Cancer cachexia refers to a multifactorial, phagocytic host wasting syndrome characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite, and muscle atrophy. It is due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with a variety of treatments, such as progestins, corticosteroids, and combination therapies. Among these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, while a corticosteroid helps reduce inflammation and suppress overactive immune systems.

The increasing prevalence of cancer and cachexia, especially among growing geriatric populations, is facilitating the demand for advanced therapeutic treatments and drugs, which in turn, are mainly driving the growth of the market. This is further supported by growing consumer awareness regarding the availability of new therapeutic drugs to treat cancer cachexia.

Moreover, the changing inclination of patients towards combination therapies to improve lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials acts as another growth inducing factor. In this light, the extensive use of several appetite stimulants such as megestrol acetate, dexamethasone, and methylprednisolone to improve digestion is also contributing to the growth of the market.

Additionally, significant technological advancements that focus on the development of effective drugs for the treatment of cancer cachexia further propel the growth of the market. Apart from this, the many supportive initiatives undertaken by government agencies of various countries and Non-Governmental Organizations (NGOs) to create awareness among the people about the causes of cancer cachexia, their symptoms and the benefits of using advanced treatments create a positive outlook for the market.

Competitive landscape

The competitive landscape of the industry was also reviewed along with the profiles of major players namely AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.

Key questions answered by this report

  • How has the global cancer cachexia market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Global Cancer Cachexia Market?
  • What are the main regional markets?
  • What is the breakout of the therapeutic-based market?
  • What is the market breakdown by mode of action?
  • What is the market breakdown by distribution channel?
  • What are the different stages of the industry value chain?
  • What are the key drivers and challenges in the industry?
  • What is the structure of the global cancer cachexia market and who are the key players?
  • How competitive is the industry?


Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Cachexia Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakdown by Therapeutics
6.1 Progestins
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Corticosteroids
6.2.1 Market trends
6.2.2 Market Forecast
6.3 Combination therapy
6.3.1 Market trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market trends
6.4.2 Market Forecast

7 Market Breakdown by Mode of Action
7.1 Appetite Stimulants
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Weight Loss Stabilizers
7.2.1 Market trends
7.2.2 Market Forecast

8 Market Breakdown by Distribution Channel
8.1 Hospital stores
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Retail pharmacy
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Online pharmacy
8.3.1 Market trends
8.3.2 Market Forecast

9 Market Breakdown by Region

10 SWOT Analysis

11 Value chain analysis

12 Analysis of the five forces of carriers

13 Price Analysis

14 Competitive landscape
14.1 Market structure
14.2 Major Players
14.3 Profiles of Key Players
14.3.1 AAVogen Inc.
14.3.1.1 Company overview
14.3.1.2 Product Portfolio
14.3.2 Actimed Therapeutics Ltd.
14.3.2.1 Presentation of the company
14.3.2.2 Product portfolio
14.3.3 Aphios Company
14.3.3.1 Company overview
14.3.3.2 Product Portfolio
14.3.4 Artelo Biosciences Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Finance
14.3.5 AVEO Pharma Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Finance
14.3.5.4 SWOT Analysis
14.3.6 Fresenius Kabi AG (Fresenius SE & Co. KGaA)
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 SWOT Analysis
14.3.7 Helsinn Healthcare AG
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Merck & Co. Inc.
14.3.8.1 Company Overview
14.3.8.2 Product portfolio
14.3.8.3 Finance
14.3.8.4 SWOT Analysis
14.3.9 NGM Biopharmaceuticals Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Finance
14.3.10 Pfizer Inc.
14.3.10.1 Company Overview
14.3.10.2 Product portfolio
14.3.10.3 Finance
14.3.10.4 SWOT Analysis
14.3.11 Tetra Bio-Pharma
14.3.11.1 Company Overview
14.3.11.2 Product portfolio
14.3.11.3 Finance

For more information about this report visit https://www.researchandmarkets.com/r/v6mh9e

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

About Terry Gongora

Check Also

Cagr Status, Industry Growth, Trends, Analysis & Forecast To 2028 | Combi-Blocks, Pfizer, DSM Sinochem Pharmaceuticals, Cadila Pharmaceuticals, Sun Pharmaceutical Industries, etc.

Atorvastatin Market Atorvastatin Market Report Coverage: Key Growth Drivers and Challenges, Regional Segmentation and …